HeartSciences (HSCS) Cash from Investing Activities (2022 - 2025)
HeartSciences (HSCS) posted quarterly Cash from Investing Activities of -$15770.0 for Q4 2025, down 169.94% year-on-year from $22547.3 in Q4 2024, and down 1837.35% on a QoQ basis from -$814.0 in Q3 2025.
HeartSciences (HSCS) Cash from Investing Activities (2022 - 2025) Analysis & Trends
HeartSciences (HSCS) has reported Cash from Investing Activities for 4 consecutive years, with -$15770.0 the latest figure, recorded in Q4 2025.
- Quarterly Cash from Investing Activities fell 169.94% year-over-year to -$15770.0 in Q4 2025, while the trailing twelve-month figure through Apr 2026 was -$24396.0 (up 19.19% YoY) and the FY2026 annual result came in at -$44452.0, down 47.25% from the prior year.
- Cash from Investing Activities slipped to -$15770.0 in Q4 2025 per HSCS's latest filing, from -$814.0 in the prior quarter.
- Over the last five years, Cash from Investing Activities for HSCS reached as high as -$814.0 in Q3 2025 and fell as low as -$69228.0 in Q2 2024.
- A 4-year average of -$14642.4 and a median of -$7247.0 in 2022 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2024 — Cash from Investing Activities sank 1317.73% — and 2025, when it surged 88.72%.
- Year by year, Cash from Investing Activities stood at -$7247.0 in 2022, then soared by 73.06% to -$1952.0 in 2023, then plunged by 199.28% to -$5842.0 in 2024, then plunged by 169.94% to -$15770.0 in 2025.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$15770.0, -$814.0, and -$7812.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.61 Bn | 175.32 Bn | 6.27 Bn | -20.32 Bn |
| 2 | Stryker | 128.95 Bn | 126.07 Bn | 3.81 Bn | -185.00 Mn |
| 3 | Medtronic | 108.22 Bn | 99.00 Bn | 6.41 Bn | -917.00 Mn |
| 4 | Boston Scientific | 68.29 Bn | 66.84 Bn | 3.61 Bn | -591.00 Mn |
| 5 | Edwards Lifesciences | 48.30 Bn | 44.63 Bn | 1.29 Bn | -92.80 Mn |
| 6 | Dexcom | 28.31 Bn | 27.19 Bn | 750.30 Mn | -298.50 Mn |
| 7 | GE HealthCare Technologies | 28.03 Bn | 25.75 Bn | 1.98 Bn | -2.50 Bn |
| 8 | Smith & Nephew | 27.01 Bn | 26.43 Bn | - | - |
| 9 | Koninklijke Philips | 24.04 Bn | 20.91 Bn | 2.07 Bn | -475.32 Mn |
| 10 | HeartSciences | 6.46 Mn | 4.76 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Oct 31, 2025 | -15,770.00 |
| Oct 31, 2025 | -15,770.00 |
| Jul 31, 2025 | -814.00 |
| Jul 31, 2025 | -814.00 |
| Apr 30, 2025 | -7,812.00 |
| Apr 30, 2025 | -7,812.00 |
| Jan 31, 2025 | -15,701.00 |
| Jan 31, 2025 | -15,701.00 |
| Oct 31, 2024 | -5,842.00 |
| Oct 31, 2024 | -5,842.00 |
| Jul 31, 2024 | -833.00 |
| Jul 31, 2024 | -833.00 |
| Apr 30, 2024 | -69,228.00 |
| Apr 30, 2024 | -69,228.00 |
| Jan 31, 2024 | -49,181.00 |
| Jan 31, 2024 | -49,181.00 |
| Oct 31, 2023 | -1,952.00 |
| Oct 31, 2023 | -1,952.00 |
| Jul 31, 2023 | -4,910.00 |
| Jul 31, 2023 | -4,910.00 |